ASSET PURCHASE AGREEMENT WITH TRIMARAN (Details Narrative) - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Aug. 19, 2019 |
Dec. 31, 2020 |
Dec. 31, 2019 |
|
| Research and development expenses | $ 36,157,000 | $ 18,192,000 | |
| WSU License Agreement [Member] | |||
| Reimbursement of patent expenses | $ 75,000 | ||
| Percentage of third party royalties payable for reduction in royalties payable | 50.00% | ||
| Maximum percentage reduction of royalties payable | 50.00% | ||
| Contingent milestone payment obligation | $ 3,400,000 | ||
| TRImaran Pharma Inc [Member] | Asset Purchase Agreement [Member] | |||
| Payment for purchase of assets | 100,000 | ||
| Liabilities assumed | 68,500 | ||
| Achievement payments payable | 3,400,000 | ||
| Research and development expenses | $ 168,500 | ||
| X | ||||||||||
- Definition The amount upon the achievement of specified development, regulatory and sales milestones, Tonix also agreed to pay TRImaran and the Selling Shareholders, in restricted stock or cash, at Tonix’s option per agreement. No definition available.
|
| X | ||||||||||
- Definition The amount of obligation to make contingent milestone payments to Columbia on a Product-by-Product basis upon the achievement of certain development, approval and sales milestones related to a specific products per license agreements. No definition available.
|
| X | ||||||||||
- Definition The maximum percentage by which royalties payable may be reduced. No definition available.
|
| X | ||||||||||
- Definition The percentage of royalties payable to any third party for intellectual property rights which are necessary for the practice of the rights licensed which may reduce royalties payable on net sales. No definition available.
|
| X | ||||||||||
- Definition The amount paid for reimbursement of patent expenses. No definition available.
|
| X | ||||||||||
- Definition Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|